$273 Million is the total value of Omega Fund Management, LLC's 19 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 19.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REPL | Sell | Replimune Group | $74,056,000 | -9.3% | 4,288,154 | -8.2% | 27.12% | +4.0% |
| Imago Biosciences | $45,432,000 | +12.4% | 3,018,737 | 0.0% | 16.64% | +29.0% | ||
| NUVB | Sell | Nuvation Bio | $33,762,000 | -31.7% | 15,072,340 | -1.1% | 12.36% | -21.6% |
| Sell | Cincor Pharma | $18,412,000 | +1.1% | 560,985 | -41.9% | 6.74% | +16.1% | |
| GOSS | Gossamer Bio | $17,970,000 | +43.1% | 1,500,000 | 0.0% | 6.58% | +64.2% | |
| MORF | Sell | Morphic Holding | $16,916,000 | -22.9% | 597,723 | -40.9% | 6.20% | -11.5% |
| ALPN | Alpine Immune Sciences | $14,613,000 | -15.4% | 2,029,580 | 0.0% | 5.35% | -2.9% | |
| KRON | Kronos Bio | $12,791,000 | -8.0% | 3,818,283 | 0.0% | 4.68% | +5.6% | |
| IKNA | Ikena Oncology | $7,984,000 | -19.9% | 2,249,123 | 0.0% | 2.92% | -8.1% | |
| IMUX | Immunic Inc | $5,651,000 | -8.9% | 1,788,160 | 0.0% | 2.07% | +4.4% | |
| PRTK | Paratek Pharmaceuticals | $5,066,000 | +33.2% | 1,971,241 | 0.0% | 1.86% | +52.8% | |
| SANA | Sana Biotechnology, Inc. | $5,063,000 | -6.7% | 843,750 | 0.0% | 1.85% | +7.0% | |
| OMEG | Omega Alpha SPAC | $4,975,000 | +0.8% | 501,000 | 0.0% | 1.82% | +15.7% | |
| Theseus Pharmaceuticals | $4,127,000 | +4.9% | 711,479 | 0.0% | 1.51% | +20.3% | ||
| SPRB | Spruce Biosciences | $2,961,000 | -21.2% | 2,161,022 | 0.0% | 1.08% | -9.7% | |
| New | Syros Pharmaceuticals | $1,618,000 | – | 251,270 | +100.0% | 0.59% | – | |
| JNCE | Jounce Therapeutics | $645,000 | -22.8% | 275,513 | 0.0% | 0.24% | -11.6% | |
| EPIX | ESSA Pharma | $597,000 | -42.3% | 328,196 | 0.0% | 0.22% | -33.6% | |
| Senti Biosciences, Inc. | $425,000 | +10.1% | 195,792 | 0.0% | 0.16% | +26.8% | ||
| IMCR | Exit | Immunocore Holdingsads | $0 | – | -51,535 | -100.0% | -0.61% | – |
| SYRS | Exit | Syros Pharmaceuticals | $0 | – | -2,512,705 | -100.0% | -0.77% | – |
| ARQT | Exit | Arcutis Biothereapeutics | $0 | – | -623,836 | -100.0% | -4.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.